| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 启迪古汉集团股份有限公司是一家集中成药、西药制剂和生化制药为一体,主要生产以"古汉养生精"为代表的中药系列产品,以各类输液为代表的西药制剂系列产品,以及以"人血白蛋白"为代表的血液制品系列产品,为湖南省高新技术企业,属医药制造行业,是全国中成药工业重点企业五十强之一,全国目前最大的中、西、生化制药联合生产企业之一.公司主要致力于研究、开发中国中药传统秘方、验方、西药制剂和生物制品,拥有古汉养生精(口服液、片剂)、优力康、心脑保泰口服液、古汉葆春栓、清暑解毒冲剂、西汉古酒等八大剂型63个品种中成药、保健品和盐酸洛美沙星注射液、克林霉素磷酸酯注射液、大输液等七大剂型147个品种的西药制剂以及人血蛋白注射液、人免疫球蛋白注射液等40多个品种的生物药品,产品销售海内外.公司系湖南最大的中、西、生化联合制药企业、全国中成药工业重点企业五十强和全国最大输液生产企业之一。 | ||||||||||||||||||||||||
| Main Business | 研究、开发中国中药传统秘方、验方和西药制剂，生产古汉养生精（口服液、片剂）、养心定悸颗粒、健肾壮腰丸等中成药以及大容量注射剂、原料药、五维赖氨酸口服溶液等西药制剂。 | ||||||||||||||||||||||||
| Legal Representative | 焦祺森 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 颜立军 | ||||||||||||||||||||||||
| Solicitors | 北京市嘉源律师事务所 | ||||||||||||||||||||||||
| Auditors | 天职国际会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 0734-8239335 | ||||||||||||||||||||||||
| Fax No | 0734-8239335 | ||||||||||||||||||||||||
| Website | www.tuspharma.cn | ||||||||||||||||||||||||
| qdyy@tuspharma.cn；qdyy0008@tuspharma.cn | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 19/01/1996 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 0.105 | ||||||||||||||||||||||||
| DPS(RMB)* | -- | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 3.022 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 1.750B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Chiyu Banking Corporation Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |